Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.14, while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| NVDW | VRTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $52.33 | $557.96 |
52-Week Low | $31.88 | $376.62 |
Market Cap | — | $134.06B |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW (Roundhill NVDA WeeklyPay ETF) trades at $37.60, down 3.22% with a bullish technical signal from moving averages. The ETF provides leveraged exposure to Nvidia with weekly dividend payments, though key valuation ratios remain unavailable. Recent news highlights its high-yield income strategy tied to NVDA's performance, with payouts fluctuating based on underlying stock volatility.
The outlook depends heavily on Nvidia's continued earnings strength and AI market momentum. Key risks include leverage amplification during NVDA downturns and variable dividend sustainability. Investors seeking weekly income from tech exposure may find value, but must monitor NAV erosion risks amid sector volatility.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
